申请人:Boehringer Mannheim GmbH
公开号:US04948809A1
公开(公告)日:1990-08-14
The present invention provides sulphonylphenylalkylamines of the general formula: ##STR1## wherein R.sub.1 is an alkyl radical containing up to 6 carbon atoms, a cycloalkyl radical containing 3-7 carbon atoms or an aralkyl, aralkenyl or aryl radical, the aryl moiety, in each case, being optionally substituted one or more times by halogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, hydroxyl, trifluoromethyl, cyano, nitro, amino, C.sub.1 -C.sub.6 alkylamino, C.sub.2 -C.sub.12 dialkylamino, C.sub.1 -C.sub.6 acylamino, C.sub.1 -C.sub.16 acyl or azide, R.sub.2 is a hydrogen atom, an alkyl radical containing up to 6 carbon atoms, an acyl radical or an aralkyl or aralkenyl radical, the aryl moiety, in each case, optionally being substituted one or more times by halogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, hydroxyl, trifluoromethyl, cyano, nitro, amino, C.sub.1 -C.sub.6 alkylamino, C.sub.1 -C.sub.12 dialkylamino, C.sub.1 -C.sub.6 acylamino, C.sub.1 -C.sub.16 acyl or azide, B is an unbranched or branched alkylene chain with a maximum of 4 carbon atoms and A an alkyl or alkenyl radical containing up to 6 carbon atoms, a C.sub.1 -C.sub.6 formylalkyl radical, a C.sub.1 -C.sub.6 hydroxy-alkyl group or a radical --D--R.sub.3, in which D is a ##STR2## and R.sub.3 is a hydrogen atom, a C.sub.1 -C.sub.5 alkyl, a C.sub.1 -C.sub.5 hydroxyalkyl or a C.sub.1 -C.sub.5 alkylcarboxylic acid radical, as well as the pharmacologically acceptable salts thereof, the esters and amides thereof and the lactones of those compounds which contain a hydroxyl and a carboxyl group, with the exception of the compound benzene-sulphonic acid-(4-acetylphenethylamide). The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.
本发明提供了通式为:##STR1##的磺胺基苯基烷胺化合物,其中R.sub.1是含有最多6个碳原子的烷基基团,含有3-7个碳原子的环烷基基团或芳基、芳烯基或芳基基团,每种情况下,芳基部分可以选择性地被卤素、C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6烷氧基、羟基、三氟甲基、氰基、硝基、氨基、C.sub.1 -C.sub.6烷基氨基、C.sub.2 -C.sub.12二烷基氨基、C.sub.1 -C.sub.6酰氨基、C.sub.1 -C.sub.16酰基或叠氮基取代一次或多次,R.sub.2是氢原子、含有最多6个碳原子的烷基基团、酰基基团或芳基或芳烯基基团,每种情况下,芳基部分可以选择性地被卤素、C.sub.1 -C.sub.6烷基、C.sub.1 -C.sub.6烷氧基、羟基、三氟甲基、氰基、硝基、氨基、C.sub.1 -C.sub.6烷基氨基、C.sub.1 -C.sub.12二烷基氨基、C.sub.1 -C.sub.6酰氨基、C.sub.1 -C.sub.16酰基或叠氮基取代一次或多次,B是最多含有4个碳原子的直链或支链烷基链,A是含有最多6个碳原子的烷基或烯基基团、C.sub.1 -C.sub.6甲酰烷基基团、C.sub.1 -C.sub.6羟基烷基或基团--D--R.sub.3,其中D是##STR2##,R.sub.3是氢原子、C.sub.1 -C.sub.5烷基、C.sub.1 -C.sub.5羟基烷基或C.sub.1 -C.sub.5烷基羧酸基团,以及其药理学上可接受的盐、酯和酰胺以及含有它们的那些含有羟基和羧基的化合物的内酯,但不包括苯磺酸-(4-乙酰基苯乙酰胺)化合物。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。